KR101876240B1 - 벤즈이미다졸 호흡기 세포융합 바이러스 억제제 - Google Patents

벤즈이미다졸 호흡기 세포융합 바이러스 억제제 Download PDF

Info

Publication number
KR101876240B1
KR101876240B1 KR1020137016944A KR20137016944A KR101876240B1 KR 101876240 B1 KR101876240 B1 KR 101876240B1 KR 1020137016944 A KR1020137016944 A KR 1020137016944A KR 20137016944 A KR20137016944 A KR 20137016944A KR 101876240 B1 KR101876240 B1 KR 101876240B1
Authority
KR
South Korea
Prior art keywords
compound
compounds
formula
group
rsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137016944A
Other languages
English (en)
Korean (ko)
Other versions
KR20140025321A (ko
Inventor
루드빅 파울 쿠이만스
사무엘 도미니크 데민
릴리 후
팀 휴고 마리아 욘커스
피에르 쟝-마리 베르나르 라보이송
압델라 타리
산드린느 마리 헬렌 벤데빌르
Original Assignee
얀센 사이언시즈 아일랜드 유씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101876240(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 사이언시즈 아일랜드 유씨 filed Critical 얀센 사이언시즈 아일랜드 유씨
Publication of KR20140025321A publication Critical patent/KR20140025321A/ko
Application granted granted Critical
Publication of KR101876240B1 publication Critical patent/KR101876240B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020137016944A 2010-12-16 2011-12-16 벤즈이미다졸 호흡기 세포융합 바이러스 억제제 Expired - Fee Related KR101876240B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10195467 2010-12-16
EP10195467.5 2010-12-16
PCT/EP2011/073008 WO2012080446A1 (en) 2010-12-16 2011-12-16 Benzimidazole respiratory syncytial virus inhibitors

Publications (2)

Publication Number Publication Date
KR20140025321A KR20140025321A (ko) 2014-03-04
KR101876240B1 true KR101876240B1 (ko) 2018-08-02

Family

ID=43875271

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016944A Expired - Fee Related KR101876240B1 (ko) 2010-12-16 2011-12-16 벤즈이미다졸 호흡기 세포융합 바이러스 억제제

Country Status (30)

Country Link
US (1) US8865705B2 (enExample)
EP (1) EP2651903B1 (enExample)
JP (1) JP6005656B2 (enExample)
KR (1) KR101876240B1 (enExample)
CN (2) CN103313974A (enExample)
AR (1) AR085203A1 (enExample)
AU (1) AU2011343255B2 (enExample)
BR (1) BR112013012137A2 (enExample)
CA (1) CA2821999C (enExample)
CL (1) CL2013001713A1 (enExample)
CY (1) CY1117751T1 (enExample)
DK (1) DK2651903T3 (enExample)
EA (1) EA022972B1 (enExample)
ES (1) ES2576180T3 (enExample)
HK (1) HK1247616A1 (enExample)
HR (1) HRP20160650T1 (enExample)
HU (1) HUE029247T2 (enExample)
IL (1) IL225640A (enExample)
MX (1) MX340030B (enExample)
MY (1) MY156641A (enExample)
NZ (1) NZ609450A (enExample)
PH (1) PH12013500796A1 (enExample)
PL (1) PL2651903T3 (enExample)
PT (1) PT2651903E (enExample)
SG (1) SG190766A1 (enExample)
SI (1) SI2651903T1 (enExample)
TW (1) TWI530495B (enExample)
UA (1) UA112298C2 (enExample)
WO (1) WO2012080446A1 (enExample)
ZA (1) ZA201304424B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
PT2864323T (pt) * 2012-06-15 2017-07-14 Janssen Sciences Ireland Uc Derivados de 1,3-di-hidro-2h-benzimidazol-2-ona substituídos com heterociclos como agentes antivirais do vírus sincicial respiratório
AU2013276520A1 (en) * 2012-06-15 2014-12-04 Janssen Sciences Ireland Uc 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
CN104487431B (zh) * 2012-07-10 2017-06-09 弗·哈夫曼-拉罗切有限公司 治疗和预防呼吸道合胞体病毒感染的新吲唑类化合物
LT2909195T (lt) 2012-10-16 2017-09-25 Janssen Sciences Ireland Uc Antivirusiniai rsv junginiai
AU2014209853B2 (en) * 2013-01-28 2017-12-21 Janssen Sciences Ireland Uc Quinoxalinones and dihydroquinoxalinones as respiratory syncytial virus antiviral agents
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
WO2014184163A1 (en) 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
RU2016105969A (ru) * 2013-08-15 2017-09-20 Ф. Хоффманн-Ля Рош Аг Новые азаоксоиндолы для лечения и профилактики респираторно-синцитиальной вирусной инфекции
HK1225716A1 (zh) 2013-08-21 2017-09-15 Alios Biopharma, Inc. 抗病毒化合物
WO2015065336A1 (en) * 2013-10-29 2015-05-07 Medivir Ab Respiratory syncytial virus inhibitors
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
EP3177299A4 (en) * 2014-08-05 2018-04-04 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
AU2016297024B2 (en) 2015-07-22 2021-03-04 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
AU2018221820B2 (en) 2017-02-16 2023-11-02 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
MX394621B (es) 2017-11-13 2025-03-24 Enanta Pharm Inc Procesos para la resolucion de los derivados de la benzodiazepina-2-ona y de la benzoazepin-2-ona
JP7558189B2 (ja) 2019-03-18 2024-09-30 エナンタ ファーマシューティカルズ インコーポレイテッド Ｒｓｖ阻害剤としてのベンゾジアゼピン誘導体
CA3153297A1 (en) 2019-10-04 2021-04-08 Adam SZYMANIAK Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2021250180A1 (en) 2020-06-11 2021-12-16 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
WO2022182861A1 (en) 2021-02-26 2022-09-01 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024174953A1 (zh) * 2023-02-21 2024-08-29 苏州隆博泰药业有限公司 苯并咪唑类衍生物及其医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095910A1 (en) 2000-06-13 2001-12-20 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2259573A1 (en) 1996-07-08 1998-01-15 Ruth Richmond Wexler Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of factor xa and of thrombin
WO2000020400A1 (en) 1998-10-05 2000-04-13 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
EA005027B1 (ru) 1999-06-28 2004-10-28 Янссен Фармацевтика Н.В. Ингибиторы репликации респираторно-синцитиального вируса
CA2376781A1 (en) 1999-06-28 2001-01-04 Janssen Pharmaceutica N.V. Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
AU2003294249A1 (en) 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095910A1 (en) 2000-06-13 2001-12-20 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic Medicinal Chemistry Letters, 17(16), 4592-2598, 2007

Also Published As

Publication number Publication date
WO2012080446A1 (en) 2012-06-21
TWI530495B (zh) 2016-04-21
JP2013545785A (ja) 2013-12-26
NZ609450A (en) 2014-10-31
CL2013001713A1 (es) 2013-10-11
AU2011343255B2 (en) 2014-12-11
SG190766A1 (en) 2013-07-31
MY156641A (en) 2016-03-15
CA2821999A1 (en) 2012-06-21
PT2651903E (pt) 2016-06-17
ES2576180T3 (es) 2016-07-06
MX2013006886A (es) 2013-07-05
CN103313974A (zh) 2013-09-18
EA201390888A1 (ru) 2013-12-30
HUE029247T2 (en) 2017-02-28
TW201305142A (zh) 2013-02-01
JP6005656B2 (ja) 2016-10-12
IL225640A (en) 2015-02-26
SI2651903T1 (sl) 2016-07-29
PL2651903T3 (pl) 2016-10-31
AU2011343255A1 (en) 2013-05-02
PH12013500796A1 (en) 2013-06-24
UA112298C2 (uk) 2016-08-25
US20130267508A1 (en) 2013-10-10
CN107417683A (zh) 2017-12-01
KR20140025321A (ko) 2014-03-04
BR112013012137A2 (pt) 2016-08-16
US8865705B2 (en) 2014-10-21
HRP20160650T1 (hr) 2016-07-15
ZA201304424B (en) 2014-12-23
MX340030B (es) 2016-06-21
HK1247616A1 (zh) 2018-09-28
EP2651903A1 (en) 2013-10-23
DK2651903T3 (da) 2016-06-27
EA022972B1 (ru) 2016-03-31
IL225640A0 (en) 2013-06-27
CA2821999C (en) 2019-02-26
EP2651903B1 (en) 2016-03-23
AR085203A1 (es) 2013-09-18
CY1117751T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
KR101876240B1 (ko) 벤즈이미다졸 호흡기 세포융합 바이러스 억제제
KR101876238B1 (ko) 호흡기 세포융합 바이러스 항바이러스제로서의 아자벤즈이미다졸
TWI515187B (zh) 作為呼吸道融合病毒抗病毒劑之吲哚類
KR101876791B1 (ko) 호흡기 세포융합 바이러스 항바이러스제로서의 아자인돌
KR101876792B1 (ko) 호흡기 세포융합 바이러스 항바이러스제로서의 이미다조피리딘
EP2864323B1 (en) 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
AU2013276520A1 (en) 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
KR20150110569A (ko) 호흡기 합포체 바이러스의 항바이러스제로서의 퀴녹살리논 및 디하이드로퀴녹살리논
JP2015519387A (ja) Ｒｓウイルス抗ウイルス薬としての、複素環によって置換された新規４−置換１，３−ジヒドロ−２ｈ−ベンゾイミダゾル−２−オン誘導体
JP2015522052A (ja) 呼吸器合胞体ウイルス感染症の治療及び予防のための新規インダゾール
AU2006260969A1 (en) 1- ( 2-amino-3- (substituted alkyl)-3H-benzimidazolylmethyl) -3-substituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus
HK1185065A (en) Benzimidazole respiratory syncytial virus inhibitors
HK1185613B (en) Indoles as respiratory syncytial virus antiviral agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230704

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230704